Herbal remedies have been used for thousands of years in worldwide traditional medicines for their potential health benefits. Although they are generally presumed safe unless a significant risk has been identified in humans, increasing number of case reports notify acute or chronic intoxications resulting from their use. This study aims to produce a scientific guide for the evaluation of traditional herbal medicines (THMs) in terms of their toxicity risks based on the published regulatory documents. For this purpose recommended in vitro and in vivo toxicity tests on medicinal products for human use issued by the international regulatory bodies are overviewed and they are then adopted to be used for the toxicity assessment of THMs. Accordingly, based on compilation of these issued regulations, the following tests are recommended for the toxicity assessment of THMs; in vitro cytotoxicity, genotoxicity, acute and repeated dose toxicity, carcinogenicity, reproductive and developmental toxicity, local tolerance tests, toxicokinetic studies, and additional toxicity tests including safety pharmacology, immunotoxicity and antigenicity, endocrine system toxicity, gastro-intestinal toxicity, renal and hepatotoxicity, and drug interaction studies. This study describes and discusses the applicability of these tests for the risk assessment in THMs.
LicataA., MacalusoF.S. (2012) Herbal hepatotoxicity: a hidden epidemic. International Emergency Medicine, doi 10.1007/s11739-012-0777-x.
2.
BhowmikD., Chiranjib DubeyP., ChandiraM., KumarK.P.S. (2009) Herbal drug toxicity and safety evaluation of traditional medicines. Archives of Applied Science Research, 1, 32–56.
3.
SchilterB., AnderssonC., AntonV., ConstableA., KleinerJ., O'BrienJ., RenwickA.G., KorverO., SmitF., WalkerR. (2003) Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food and Chemical Toxicology, 41, 1625–1649.
4.
ChhabraR.S., BucherJ.R., WolfeM., PortierC. (2003) Toxicity characterization of environmental chemicals by the US National Toxicology Programme: an overview. International Journal of Hygiene and Environmental Health, 206, 437–445.
5.
EU Directive. (2004) 2004/24/ EC of the European Parliament and of the Council of 31 March 2004, amending, as regards traditional herbal medicinal products. Directive 2001/83/EC on the Community code relating to medicinal products for human use.
6.
EU Directive. (2001) 2001/83/ EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
7.
AmreshG., SinghP.N., RaoC.V. (2008) Toxicological screening of traditional medicine Laghupatha (Cissampelos pareira) in experimental animals. Journal of Ethnopharmacology, 116, 454–460.
8.
ColsonC.R.D., De BroeM.E. (2005) Kidney injury from alternative medicines. Advances in Chronic Kidney Disease, 12, 261–275.
9.
SinghY.N., DevkotaA.K., SneedenD.C., SinghK.K., HalaweishF. (2007) Hepatotoxicity potential of Saw Palmetto (Serenoa repens) in rats. Phytomedicine, 14, 204–208.
10.
IsbruckerR.A., BurdockG.A. (2006) Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regulatory Toxicology and Pharmacology, 46, 167–192.
11.
CañigueralS., TschoppR., AmbrosettiL., VignutelliA., ScaglioneF., PetriniO. (2008) The development of herbal medicinal products: Quality, safety and efficacy as key factors. Pharmaceutical Medicine, 22, 107–118.
12.
WHO 93. (1993) Research guidelines for evaluating the safety and efficacy of herbal medicines.World Health Organization Regional Office for the Western Pacific, Manila.
13.
EMEA. (2006) EMEA/HMPC/32116/2005. Guideline on non-clinical documentation for herbal medicinal products in applications for marketing authorisation (bibliographical and mixed applications) and in applications for simplified registration. 7 September 2006.
14.
ButterworthB.E. (2006) A classification framework and practical guidance for establishing a mode of action for chemical carcinogens. Regulatory Toxicology and Pharmacology, 45, 9–23.
15.
SaitoD., ShiraiA., MatsushimaT., SugimuraT., HironoI. (1980) Test of carcinogenity of quercetin, a widely distributed mutagen in food. Teratogenesis, Carcinogenesis and Mutagenesis, 1, 213–221.
16.
SeinoY., NaganoM., YahagiT., SugimuraT., YasudaT., NishimuraS. (1978) Identification of a mutagenic substance in a spice, sumac, as quercetin. Mutation Research, 58, 225–9.
17.
NTP Technical Report. (1991) NTP Technical Report no. 409 on the toxicology and carcinogenesis studies of quercetin in F344/N rats. NIH Publication No. 91–3140, NC.
18.
IkegamiF., FujiiY., IshiharaK., SatohT. (2003) Toxicological aspects of Kampo medicines in clinical use. Chemico-Biological Interactions, 145, 235–250.
19.
AkinboroA., BakareA.A. (2007) Cytotoxic and genotoxic effects of aqueous extracts of five medicinal plants on Allium cepa Linn. Journal of Ethnopharmacology, 112, 470–475.
20.
LjubuncicP., AzaizehH., PortnayaI., CoganU., SaidO., Abu SalehK., BomzonA. (2005) Antioxidant activity and cytotoxicity of eight plants used in traditional Arab medicine in Israel. Journal of Ethnopharmacology, 99, 43–47.
21.
Romero-JimenezM., Campos-SanchezJ., AnallaM., Munoz-SerranoA., Alonso-MoragaA. (2005) Genotoxicity and anti-genotoxicity of some traditional medicinal herbs. Mutation Research, 585, 147–155.
22.
BarlowS.M., GreigJ.B., BridgesJ.W., CarereA., CarpyA.J.M., GalliC.L., KleinerJ., KnudsenI., KoeterHBWM, LevyL.S., MadsenC., MayerS., NarbonneJ-F, PfannkuchF., ProdanchukM.G., SmithM.R., SteinbergP. (2002) Hazard identification by methods of animal-based toxicology. Food and Chemical Toxicology, 40, 145–191.
23.
AnsahC., KhanA., GooderhamN.J. (2005) In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepine. Toxicology, 208, 141–147.
24.
BhattaramV.A., GraefeU., KohlertC., VeitM., DerendorfH. (2002) Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine, 9, (Supplement III), 1–33
25.
International Organization for Standardization (ISO) (2009) 10993–5:2009 Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity.
26.
WiesnerJ. (2014) Challenges of safety evaluation. Journal of Ethnopharmacology, 158, 467–470.
27.
RamachandranS., VamsikrishnaM., GowthamiK.V., HeeraB., DhanarajuM.D. (2011) Assessment of cytotoxic activity of Agave cantula using brine shrimp (Artemia salina) lethality bioassay. Asian Journal of Scientific Research, 4, 90–94.
28.
United States Environmental Protection Agency (EPA). (2002) EPA-821-R-02-012. Methods for measuring the acute toxicity of effluents and receiving waters to freshwater and marine organisms.
29.
SvenssonB.M., MathiassonL., MårtenssonL., BergströmS. (2005) Artemia salina as test organism for assessment of acute toxicity of leachate water from landfills. Environmental Monitoring and Assessment, 102, 309–321.
30.
ButterweckV., DerendorfH., GausW., NahrstedtA., SchulzV., UngerM. (2004) Pharmacokinetic herb-drug interactions: Are preventive screenings necessary and appropriate. Planta Medica, 70, 784–791.
31.
ThybaudV., AardemabM., ClementsJ., DearfieldK., GallowayS., HayashiM., Jacobson-KramD., KirklandD., MacGregorJ.T., MarzinD., OhyamajW., SchulerM., SuzukiH., ZeigerE. (2007) Strategy for genotoxicity testing: Hazard identification and risk assessment in relation to in vitro testing. Mutation Research, 627, 41–58.
32.
EMEA. (2007) EMEA/HMPC/107079/2007. Guideline on the assessment of genotoxic constituents in herbal substances/preparations. 31 October 2007.
33.
JenaG.B., KaulC.L., RamaraoP. (2002) Genotoxicity testing, a regulatory requirement for drug discovery and development: Impact of ICH guidelines. Indian Journal of Pharmacology, 34, 86–99.
34.
ICH Guidance. (2011) ICH harmonised tripartite guideline S2 (R1). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. Center for Drug Evaluation and Research (CDER).
35.
DinçerY., KankayaS. (2010) Comet assay for determination of DNA damage: Review. Türkiye Klinikleri (Journal of Medical Sciences), 30, 1365–1373.
36.
KasperP., UnobY., MautheR., AsanoN., DouglasG., MatthewsE., MooreM., MuellerL., NakajimaM., SingerT., SpeitG. (2007) Follow-up testing of rodent carcinogens not positive in the standard genotoxicity testing battery: IWGT workgroup report. Mutation Research, 627, 106–116.
WuK., JiangL., CaoaJ., YangG., GengbC., ZhongaL. (2007) Genotoxic effect and nitrative DNA damage in HepG2 cells exposed to aristolochic acid. Mutation Research, 630, 97–102.
39.
OECD. (1997) The OECD guidelines for the testing of chemicals: 471. Bacterial reverse mutation test.
40.
OECD. (2015) The OECD guidelines for the testing of chemicals: 476. In vitro mammalian cell gene mutation tests using the Hprt and xprt genes.
41.
Editorial. (2006) The in vitro micronucleus test: From past to future. Mutation Research, 607, 2–4.
42.
OECD. (2014) The OECD guidelines for the testing of chemicals: 487.In vitro mammalian cell micronucleus test (MNvit).
43.
AndreoliC., GiganteD., NunziataA. (2003) A review of in vitro methods to assess the biological activity of tobacco smoke with the aim of reducing the toxicity of smoke. Toxicology in Vitro, 17, 587–594.
44.
OECD. (2014) The OECD guidelines for the testing of chemicals: 475. Mammalian bone marrow chromosome aberration test.
45.
ICH Guidance. (1996) Guidance for industry. Single dose acute toxicity testing for pharmaceuticals.Center for Drug Evaluation and Research (CDER).
46.
OECD. (2001) The OECD guidelines for the testing of chemicals: 420. Acute oral toxicity – Fixed dose procedure.
47.
OECD. (2008) The OECD guidelines for the testing of chemicals: 425. Acute oral toxicity – Up-and-down-procedure (UDP).
48.
OECD. (2001) The OECD guidelines for the testing of chemicals: 423. Acute oral toxicity – Acute toxic class method.
49.
RamirezJ.H., PalaciosM., TamayobO., JaramilloR., GutierrezO. (2007) Acute and subacute toxicity of Salvia scutellarioides in mice and rats. Journal of Ethnopharmacology, 109, 348–353.
50.
RobinsonS., DelongeasJ-L, DonaldE., DreherD., FestagM., KervynS., LampoA., NahasK., NoguesV., OckertD., QuinnK., OldS., PickersgillN., SomersK., StarkC., SteiP., WatersonL., ChapmanK. (2008) A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regulatory Toxicology and Pharmacology, 50, 345–352.
51.
JohnsC. (2009) Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. Canadian Journal of Emergency Medicine, 11, 94–96.
52.
OECD. (2008) The OECD guidelines for the testing of chemicals: 407. Repeated dose 28-day oral toxicity study in rodents.
53.
OECD. (1998) The OECD guidelines for the testing of chemicals: 408. Mammalian repeated dose 90-day oral toxicity study in rodents.
54.
HartmannE., StraussV., EibenR., FreybergerA., KaufmannW., LoofI., ReissmuellerE., RinkeM., Ruehl-FehlertC., SchorschF., SchladtL. (2008) ESTP comments on the draft updated OECD test guideline 407. Experimental and Toxicologic Pathology, 59, 297–300.
55.
Kaszkin-BettagM., RichardsonA., RettenbergerR., HegerP.W. (2008) Long-term toxicity studies in dogs support the safety of the special extract ERr 731 from the roots of Rheum rhaponticum. Food and Chemical Toxicology, 46, 1608–1618.
56.
ICH Guidance. (1998) ICH harmonised tripartite guideline S4: Duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing).Center for Drug Evaluation and Research (CDER).
57.
OECD. (2009) The OECD guidelines for the testing of chemicals: 452.Chronic toxicity studies.
58.
ICH Guidance. (1995) Guideline for industry S1A: The need for long-term rodent carcinogenicity studies of pharmaceuticals.Center for Drug Evaluation and Research (CDER).
59.
OECD. (2009) The OECD guidelines for the testing of chemicals: 451.Carcinogenicity studies.
60.
OECD. (2009) The OECD guidelines for the testing of chemicals: 453. Test guideline 453: Combined chronic toxicity\carcinogenicity studies.
61.
BezG.C., JordãoB.Q., VicentiniV.E.P., MantovaniM.S. (2001) Investigation of genotoxic and antigenotoxic activities of chlorophylls and chlorophyllin in cultured V79 cells. Mutation Research, 497, 139–145.
62.
OECD. (2001) The OECD guidelines for the testing of chemicals: 414. Prenatal developmental toxicity study- proposal for updating guideline 414.
63.
United States Environmental Protection Agency (EPA). (1998) Health effects test guidelines OPPTS 870.3700 prenatal developmental toxicity study.
64.
OECD. (1983) The OECD guidelines for the testing of chemicals: 415. One-generation reproduction toxicity study.
65.
OECD. (2001) The OECD guidelines for the testing of chemicals: 416. Two-generation reproduction toxicity study.
66.
United States Environmental Protection Agency (EPA). (1998) Health effects test guidelines OPPTS 870.3800 reproduction and fertility effects.
67.
United States Environmental Protection Agency (EPA),. (2000) Health effects test guidelines OPPTS 870.3550 reproduction/developmental toxicity screening test.
68.
United States Environmental Protection Agency (EPA). (2000) Health effects test guidelines OPPTS 870.3650. Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test.
69.
OECD. (2015) The OECD guidelines for the testing of chemicals: 422. Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test.
70.
ReuterU., Heinrich-HirschB., HellwigJ., HolzumB., WelscheF. (2003) Evaluation of OECD screening tests 421 (reproduction/developmental toxicity screening test) and 422 (combined repeated dose toxicity study with the reproduction/developmental toxicity screening test). Regulatory Toxicology and Pharmacology, 38, 17–26.
71.
EMEA. (2009) CPMP/ICH/286/95. Note for guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. June 2009.
72.
ICH Guidance. (2000) ICH harmonised tripartite guideline S7A: Safety pharmacology studies for human pharmaceuticals.Center for Drug Evaluation and Research (CDER).
73.
ICH Guidance. (2005) ICH harmonised tripartite guideline S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Center for Drug Evaluation and Research (CDER).
74.
PugsleyM.K., AuthierS., CurtisM.J. (2008) Principles of safety pharmacology. British Journal of Pharmacology, 154, 1382–1399.
75.
JainA., SoniM., DebL., JainA., RoutS.P., GuptaV.B., KrishnaK.L. (2008) Antioxidant and hepatoprotective activity of ethanolic and aqueous extracts of Momordica dioica Roxb. leaves. Journal of Ethnopharmacology, 115, 61–66.
76.
ICH Guidance. (2006) Guidance for industry S8: Immunotoxicity studies for human pharmaceuticals.Center for Drug Evaluation and Research (CDER).
77.
OECD. (2007) The OECD guidelines for the testing of chemicals: 440. Uterotrophic bioassay in rodents: A short-term screening test for oestrogenic properties.
78.
YesiladaE., KüpeliE. (2002) Berberis crataegina DC. root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats. Journal of Ethnopharmacology, 79, 237–48.
79.
MillsS., BoneK. (2003) Essential Guide to Herbal Safety, 1st ed., Elsevier, Missouri, USA
80.
KishorM.W., JamesS.C. (1996) Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Antimicrobial Agents and Chemotherapy, 40, 1806–1810.
81.
ClemoF.A.S. (1998) Urinary enzyme evaluation of nephrotoxicity in the dog. Toxicologic Pathology, 26, 29–32.
82.
NavarroV.J., SeniorJ.R. (2006) Drug-related hepatotoxicity. The New England Journal of Medicine, 354, 731–9.
